Metir plc has successfully completed Phase 1 of its collaboration with Aptamer Group plc, achieving technical feasibility for novel Optimer® binders to be integrated into Metir's real-time Pathogen Detector platform for the rapid detection of *Cryptosporidium parvum* oocysts. This milestone, completed on time and budget, confirms the feasibility of developing high-affinity binders without identifying material technical barriers, paving the way for Phase 2 which aims for commercialisation by early 2027. The Pathogen Detector platform targets the $1.2 billion *Cryptosporidium* diagnostic testing market, with preliminary interest expressed by several UK water companies for trialling a proof-of-concept device.
